Benjamin L. Palleiko
2021
In 2021, Benjamin L. Palleiko earned a total compensation of $1.5M as President, Chief Business Officer and Chief Financial Officer at Carbylan Therapeutics, a 42% increase compared to previous year.
Compensation breakdown
| Bonus | $261,000 |
|---|---|
| Option Awards | $747,663 |
| Salary | $435,000 |
| Other | $15,850 |
| Total | $1,459,513 |
Palleiko received $747.7K in option awards, accounting for 51% of the total pay in 2021.
Palleiko also received $261K in bonus, $435K in salary and $15.9K in other compensation.
Rankings
In 2021, Benjamin L. Palleiko's compensation ranked 7,366th out of 12,415 executives tracked by ExecPay. In other words, Palleiko earned more than 40.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,366 out of 12,415 | 41st |
Division Manufacturing | 3,236 out of 5,508 | 41st |
Major group Chemicals And Allied Products | 1,432 out of 2,378 | 40th |
Industry group Drugs | 1,275 out of 2,099 | 39th |
Industry Pharmaceutical Preparations | 936 out of 1,549 | 40th |
Source: SEC filing on August 14, 2023.
Palleiko's colleagues
We found two more compensation records of executives who worked with Benjamin L. Palleiko at Carbylan Therapeutics in 2021.